219 related articles for article (PubMed ID: 30968600)
1. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
[TBL] [Abstract][Full Text] [Related]
2. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Tseng CH
BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
[TBL] [Abstract][Full Text] [Related]
3. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
Chen CB; Eurich DT; Majumdar SR; Johnson JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):122-126. PubMed ID: 28071672
[TBL] [Abstract][Full Text] [Related]
4. Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study.
Nørgaard M; Darvalics B; Thomsen RW
BMJ Open; 2020 Dec; 10(12):e041875. PubMed ID: 33371039
[TBL] [Abstract][Full Text] [Related]
5. The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Hong Y; Lee S; Won S
PLoS One; 2019; 14(7):e0219394. PubMed ID: 31323022
[TBL] [Abstract][Full Text] [Related]
6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk.
Hung SC; Lai SW; Tsai PY; Chen PC; Wu HC; Lin WH; Sung FC
Br J Cancer; 2013 May; 108(9):1778-83. PubMed ID: 23612451
[TBL] [Abstract][Full Text] [Related]
8. Association Between Erectile Dysfunction and Subsequent Prostate Cancer Development: A Population-Based Cohort Study With Double Concurrent Comparison Groups.
Kok VC; Hsiao YH; Horng JT; Wang KL
Am J Mens Health; 2018 Sep; 12(5):1492-1502. PubMed ID: 29708021
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
[TBL] [Abstract][Full Text] [Related]
10. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
[TBL] [Abstract][Full Text] [Related]
12. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
[TBL] [Abstract][Full Text] [Related]
13. Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Azoulay L; Dell'Aniello S; Gagnon B; Pollak M; Suissa S
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):337-44. PubMed ID: 21148757
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
Nygård LH; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate; 2023 Feb; 83(3):246-258. PubMed ID: 36325820
[TBL] [Abstract][Full Text] [Related]
15. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
16. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy.
Zaorsky NG; Shaikh T; Ruth K; Sharda P; Hayes SB; Sobczak ML; Hallman MA; Smaldone MC; Chen DY; Horwitz EM
Clin Genitourin Cancer; 2017 Apr; 15(2):326-335.e3. PubMed ID: 27789181
[TBL] [Abstract][Full Text] [Related]
18. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
19. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
BMC Cancer; 2020 Jun; 20(1):551. PubMed ID: 32539807
[TBL] [Abstract][Full Text] [Related]
20. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
Hammarsten J; Högstedt B
Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
